NSC, Sanofi, and A*STAR Partner to Advance Acne Treatment Research
NSC, Sanofi, and A*STAR Partner to Advance Acne Treatment Research
In addition, a translational study will be conducted to explore key biological markers that impact acne severity.The collaboration includes a phase 1 clinical study to start in the second quarter of 2025.
該合作包括一項將於2025年第二季度開始的1期臨床研究。
The National Skin Centre Singapore, Sanofi, and the Agency for Science, Technology, and Research (A*STAR) have signed a memorandum of understanding (MoU) to advance research in acne treatment.
新加坡國家皮膚中心、賽諾菲和科學、技術和研究局（A*STAR）簽署了一份諒解備忘錄（MoU），以推進痤瘡治療的研究。
The collaboration includes a phase 1 clinical study involving patients with mild acne, expected to commence in the second quarter of 2025.
該合作包括一項涉及輕度痤瘡患者的1期臨床研究，預計將於2025年第二季度開始。
In addition, a translational study will be conducted to explore key biological markers that impact acne severity.
此外，將進行一項轉化研究，以探索影響痤瘡嚴重程度的關鍵生物標誌物。
The chronic inflammatory skin condition affects a significant portion of the population, with approximately 80% of teenagers and an increasing number of adults—an estimated 40%—experiencing the condition.
慢性炎症性皮膚病影響了很大一部分人群，大約80％的青少年和越來越多的成年人（估計佔40％）患有這種疾病。
